Literature DB >> 10690858

Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors.

B Bülow1, L Hagmar, J Eskilsson, E M Erfurth.   

Abstract

We recently reported that female patients with hypopituitarism receiving controlled thyroid and steroid hormone substitution, but without GH replacement, had a more than 2-fold increase in cardiovascular mortality compared to the general population. In the present study we investigated the incidence of cardiovascular disease as well as the prevalence of cardiovascular risk factors in 33 females with hypopituitarism for 6-46 yr (median, 18) compared to those in 33 control subjects recruited from the general population in the same geographical area and matched for sex, age, smoking habits, educational level, and residence location. The patients were with a very high probability GH deficient, as 29 had subnormal serum insulin-like growth factor I levels, and the other 4 were GH deficient, as assessed by an insulin tolerance test. The incidence of cardiovascular disease was significantly higher among the hypopituitary patients (incidence ratio, 3.7; 95% confidence interval, 1.2-11.3), and the consumption of cardioactive drugs was also significantly higher (P = 0.002). Hypopituitary patients had a lower degree of physical exercise during their spare time (P = 0.02), a higher waist/hip ratio (P = 0.01), lower high density lipoprotein cholesterol (P = 0.002), and higher low density/high density lipoprotein ratio (P = 0.009). Furthermore, the patients had a significantly increased left atrium size (P = 0.05), but no difference was observed for other cardiac measures. In the patients, serum insulin-like growth factor I levels significantly correlated with left ventricular mass index (r = 0.48; P = 0.006), suggesting that GH has a strong impact on cardiac size. More episodes of bradycardia (P = 0.05), but no increased occurrence of extrasystolies, were encountered in the patients during 24-h continuous electrocardiogram monitoring. Carotid artery intima-media thickness and plaque numbers did not differ between patients and controls. In conclusion, hypopituitary females exhibit an increased incidence of cardiovascular disease, higher cardioactive drug consumption, and an increased prevalence of cardiovascular risk factors. The increased cardiovascular morbidity could not be ascribed to inadequate estrogen or thyroid hormone treatment, and unsubstituted GH deficiency is probably an important contributing factor.

Entities:  

Mesh:

Year:  2000        PMID: 10690858     DOI: 10.1210/jcem.85.2.6346

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency.

Authors:  Linman Li; Wei Ren; Jinchao Li; Jingjing Liu; Lingli Wang; Xiaoya Zheng; Dezhen Liu; Sufang Li; Rhonda Souvenir; Jiping Tang
Journal:  Endocrine       Date:  2012-05-29       Impact factor: 3.633

3.  Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome.

Authors:  Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Elizabeth Salles; Claúdia Medina Coeli; Flávia Lúcia Conceição; Mario Vaisman
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

4.  Cardiovascular endocrinology: Growth hormone in CVD prediction--a tall order?

Authors:  Connie W Tsao; Ramachandran S Vasan
Journal:  Nat Rev Endocrinol       Date:  2014-11-18       Impact factor: 43.330

Review 5.  Unusual effects of GH deficiency in adults: a review about the effects of GH on skin, sleep, and coagulation.

Authors:  F Tanriverdi; Z Karaca; K Unluhizarci; F Kelestimur
Journal:  Endocrine       Date:  2014-05-11       Impact factor: 3.633

Review 6.  Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials.

Authors:  Connie B Newman; John D Carmichael; David L Kleinberg
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

7.  Sex differences in the prevalence of metabolic syndrome and its components in hypopituitary patients: comparison with an age- and sex-matched nationwide control group.

Authors:  Ah Reum Khang; Eu Jeong Ku; Ye An Kim; Eun Roh; Jae Hyun Bae; Tae Jung Oh; Sang Wan Kim; Chan Soo Shin; Seong Yeon Kim; Jung Hee Kim
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

8.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

9.  The decreased growth hormone response to growth hormone releasing hormone in obesity is associated to cardiometabolic risk factors.

Authors:  Fernando Cordido; Jesús Garcia-Buela; Susana Sangiao-Alvarellos; Teresa Martinez; Ovidio Vidal
Journal:  Mediators Inflamm       Date:  2010-01-21       Impact factor: 4.711

10.  GH/GHRH axis in HIV lipodystrophy.

Authors:  Takara L Stanley; Steven K Grinspoon
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.